 |
| 28-Jan-13 | Initiated |
RBC Capital Mkts |
Sector Perform |
$14 |
|
| 23-Jul-12 | Downgrade |
Deutsche Bank |
Buy → Hold |
$15 → $14 |
|
| 23-May-12 | Initiated |
Auriga |
Buy |
$16 |
|
| 07-Mar-12 | Reiterated |
Needham |
Buy |
$13 → $14 |
|
| 23-Feb-12 | Reiterated |
Deutsche Bank |
Buy |
$13 → $15 |
|
| 18-Jan-12 | Reiterated |
Needham |
Buy |
$12 → $13 |
|
| 23-Dec-11 | Reiterated |
Deutsche Bank |
Buy |
$11 → $13 |
|
| 16-Sep-11 | Initiated |
Deutsche Bank |
Buy |
$11 |
|
| 08-Nov-10 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$5 → $8 |
|
| 15-Jul-10 | Initiated |
Rodman & Renshaw |
Mkt Outperform |
$5 |
|
| 26-Feb-09 | Reiterated |
Credit Suisse |
Outperform |
$6 → $3 |
|
| 27-Mar-07 | Reiterated |
Friedman Billings |
Outperform |
$7.50 → $8.50 |
|
|
|
| 17-May-13 01:04PM | AKORN INC Financials EDGAR Online Financials |
| 14-May-13 09:29AM | AKORN INC Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant EDGAR Online |
| 10-May-13 09:55AM | AKORN INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 08-May-13 07:33AM | Akorn sell-off on Q1 results overdone, says Leerink at theflyonthewall.com |
| 07-May-13 09:08PM | Akorn Hits Estimates in Solid Quarter at Motley Fool -7.46% |
| 06:02PM | Nasdaq stocks posting largest percentage decreases AP |
| 05:01PM | Vitamin Shoppe, Fossil, Akorn are big movers AP |
| 03:01PM | Nasdaq stocks posting largest percentage decreases AP |
| 02:41PM | Akorn's CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 01:24PM | Why Akorn Shares Were Crushed at Motley Fool |
| 11:32AM | AKRX Crosses Below Key Moving Average Level at TheStreet |
| 09:31AM | Akorn Earnings: Heres Why Investors Dont Like These Results at Wall St. Cheat Sheet |
| 07:07AM | Q1 2013 Akorn, Inc. Earnings Release - Before Market Open CCBN |
| 06:16AM | InPlay: Akorn misses by $0.03, reports revs in-line; guides FY13 EPS below consensus, revs below consensus Briefing.com |
| 06:00AM | Akorn Reports First Quarter 2013 Financial Results Business Wire |
| 02:46AM | AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition, Submission of Matters to a Vote of Secur EDGAR Online |
| 06-May-13 05:16PM | Akorn Earnings: Your Sneak Peek to the Big Announcement at Wall St. Cheat Sheet |
| 02-May-13 11:07AM | Wall Street Transcript Interview with David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co.: Alternative Dosage Forms Create Barriers Against Competition in Generics Wall Street Transcript |
| 26-Apr-13 04:00PM | Orphan Drug Status for Teva/Xenon Drug Zacks |
| 19-Apr-13 05:15PM | Favorable Court Ruling for Actavis Zacks |
| 18-Apr-13 05:50PM | Data on Teva's Milprosa Zacks |
| 15-Apr-13 04:50PM | Still Neutral on Mylan Zacks |
| 04-Apr-13 06:28PM | Dr. Reddy's Launches Generic Reclast Zacks |
| 02:05PM | Another Generic Launch at Mylan Zacks |
| 09:18AM | Teva's Quartette Approved in the US Zacks |
| 03-Apr-13 04:00PM | Akorn, Inc. Announces First Quarter 2013 Earnings Release And Conference Call Information PR Newswire |
| 12:38PM | KaloBios Pharma Incurs Wider Loss Zacks |
| 01-Apr-13 04:33PM | Dr. Reddy's Launches Generic Accutane Zacks |
| 28-Mar-13 09:17AM | AKORN INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits EDGAR Online |
| 25-Mar-13 06:18PM | Data on Teva's Azilect Zacks |
| 20-Mar-13 07:26PM | [$$] A Pharmaceutical Turnaround Story at Barrons.com |
| 11-Mar-13 03:44PM | A Quick Look At 8 Biotechs Ready To Gain Momentum at Seeking Alpha |
| 07-Mar-13 01:04PM | AKORN INC Financials EDGAR Online Financials |
| 04-Mar-13 09:47AM | 3 Earnings Reports That Caught My Attention Last Week at Motley Fool |
| 01-Mar-13 05:30PM | AKORN INC Files SEC form 10-K, Annual Report EDGAR Online |
| 01:04PM | AKORN INC Financials EDGAR Online Financials |
| 27-Feb-13 07:29PM | New Star Analyst Rankings for Akorn, Inc. StarMine |
| 26-Feb-13 08:52PM | Akorn Increases Sales but Misses Estimates on Earnings at Motley Fool |
| 03:06PM | Akorn Earnings: Heres Why Shares are Up Now at Wall St. Cheat Sheet |
| 02:58PM | Akorn's CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 12:01PM | Earnings roundup: Home Depot, MetroPCS AP |
| 11:00AM | Generic drugmaker Akorn's 4Q profit climbs 54 pct AP |
| 09:16AM | AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online |
| 07:11AM | InPlay: Akorn beats by $0.01, beats on revs Briefing.com |
| 07:07AM | Q4 2012 Akorn, Inc. Earnings Release - Before Market Open CCBN |
| 07:00AM | Akorn Reports 2012 Fourth Quarter and Year-End Financial Results Business Wire |
| 25-Feb-13 03:26PM | Companies reporting Before the Market Open on Tuesday, February 26 theflyonthewall.com |
| 01:19AM | What to Expect from Akorn at Motley Fool |
| 08-Feb-13 12:01PM | Response Genetics' Competitors: Who To Watch, Who To Worry About at Seeking Alpha |
| 05-Feb-13 04:04PM | Akorn, Inc. Announces Fourth Quarter 2012 Earnings Release And Conference Call Information PR Newswire |
| 28-Jan-13 01:03AM | Coverage initiated on Akorn by RBC Capital Mkts Briefing.com |
| 26-Jan-13 09:07AM | 1 Reason Akorn May Be Headed for a Slowdown at Motley Fool |
| 23-Jan-13 06:48PM | Do Generic-Drug Makers Belong in Your Portfolio? at Motley Fool |
| 18-Jan-13 10:40AM | Pacira Remains a Top Small Cap and 4 Stock Analyses to Note at Wall St. Cheat Sheet |
| 17-Jan-13 08:13PM | Akorn CEO Hosts 2013 Financial Guidance Conference (Transcript) at Seeking Alpha |
| 03:56PM | AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online |
| 02:37PM | InPlay: Akorn reaffirms FY12 guidance; sees FY13 EPS below consensus on in-line rev Briefing.com |
| 02:30PM | Akorn Provides Financial Guidance for 2013 Business Wire |
| 10:09AM | Boeing Expects Impact From Grounding and 4 Stock Analyses to Follow at Wall St. Cheat Sheet |
| 06:28AM | Donor Feces Cure Recurrent Diarrheal Infection, Study Shows at Bloomberg |
| 14-Jan-13 02:11PM | Akorn, Inc. To Host A Conference Call To Discuss 2013 Financial Guidance PR Newswire |
| 09-Jan-13 02:37PM | ViroPharma Suit Against FDA Over Generic Vancocin Tossed at Bloomberg |
| 20-Dec-12 05:52PM | 4 Biotech Names With Major Market Potential: Michael Higgins at Seeking Alpha |
| 17-Dec-12 01:26PM | Top Buys by Directors: Weinstein's $416.8K Bet on AKRX at Forbes |
| 11:13AM | Get An Even Better Deal On AKRX Than Director Weinstein Did at Forbes |
| 15-Nov-12 01:04PM | AKORN INC Financials EDGAR Online Financials |
| 13-Nov-12 12:37PM | American Vanguard Pullback Deemed Unwarranted and 3 Stock Analyses to Note at Wall St. Cheat Sheet |
| 09-Nov-12 05:00PM | AKORN INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 01:04PM | AKORN INC Financials EDGAR Online Financials |
| 07-Nov-12 10:07AM | Rackspace Poised For Growth and 2 Stock Analyses to Track at Wall St. Cheat Sheet |
| 09:36AM | New Star Analyst Rankings for Akorn, Inc. StarMine |
| 06-Nov-12 04:30PM | Akorn's CEO Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 01:31PM | Akorn Beats Up on Analysts Yet Again at Motley Fool |
| 09:15AM | AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online |
| 07:07AM | Q3 2012 Akorn, Inc. Earnings Release - Before Market Open CCBN |
| 06:15AM | InPlay: Akorn misses by $0.01, reports revs in-line; guides Q4 revs below consensus; reaffirms FY12 EPS guidance, revs guidance Briefing.com |
| 06:00AM | Akorn Reports Third Quarter 2012 Financial Results Business Wire |
| 25-Oct-12 12:40PM | AKORN INC Files SEC form 8-K, Other Events EDGAR Online |
| 24-Oct-12 06:10AM | Akorn announces approval and launch of generic Prometrium at theflyonthewall.com |
| 06:02AM | InPlay: Akorn announces the approval and launch of generic of Abbott's (ABT) Prometrium Briefing.com |
| 06:00AM | Akorn Announces the Approval and Launch of Generic Prometrium® Business Wire |
| 12-Oct-12 07:42AM | Why Akorn May Be About to Take Off at Motley Fool |
| 10-Oct-12 04:51PM | Akorn, Inc. Announces Third Quarter 2012 Earnings Release and Conference Call Information PR Newswire |
| 02:17PM | Akorn Receives FDA Warning and 4 Must-See Stock Analyses at Wall St. Cheat Sheet |
| 11:50AM | PropThink: FDA Warning Letter Weakens Shares of Akorn Thomson Reuters ONE |
| 07:21AM | Akorn warning letter no cause for alarm, says Piper Jaffray theflyonthewall.com |
| 09-Oct-12 09:22AM | FDA warns Akorn about manufacturing unapproved new drugs theflyonthewall.com |
| 04-Oct-12 12:40PM | PropThink: BPAX Merger A Great Deal for ANI; BPAX Could Trade Lower Thomson Reuters ONE |
| 28-Sep-12 10:24AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 26-Sep-12 01:06PM | Two Fast Growing Pharma Stocks Receiving Some Love From Analysts This Week at Seeking Alpha +5.48% |
| 12:31PM | Baxter and Other Healthcare Stocks Making Big Moves on September 26, 2012 at Investopedia |
| 10:32AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 24-Sep-12 11:36AM | InPlay: Akorn Chairman adopts 10b5-1 trading plan Briefing.com |
| 11:36AM | Akorns Chairman Adopts 10b5-1 Trading Plan Business Wire |
| 13-Sep-12 12:41PM | Amazon, Ben & Jerrys, Costco: Intellectual Property at Bloomberg |
| 07:00AM | Amazon, Ben & Jerry's, Costco: Intellectual Property at Bloomberg |
| 12:00AM | Amazon, Ben & Jerrys, Costco: Intellectual Property at Bloomberg |
| 12-Sep-12 04:10PM | Akorn Sued by Fera Over Drug Supply Pact, Trade Secrets at Bloomberg |
| 02:04PM | Napoli Bern Ripka Shkolnik, LLP Files Civil Complaint Against Akorn, Inc. -- AKRX GlobeNewswire |
| 05-Sep-12 12:31PM | AKORN INC Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online |
|
|
| Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various specialty areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, and vaccines. The company's Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others primarily for use in the office setting. This segment also offers therapeutic products, such as antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; and non-pharmaceutical products, which include various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. In addition, the Ophthalmic segment provides a line of over-the-counter dry eye and other eye health products principally under the TheraTears brand name through a chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. Its Hospital Drugs & Injectables segment provides a line of hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. The company's Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. It serves physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains, and other pharmaceutical companies. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| ABRAMOWITZ KENNETH | Director | Mar 13 | Sale | 14.02 | 1,200 | 16,824 | 21,500 | Mar 14 05:32 PM | | ABRAMOWITZ KENNETH | Director | Mar 12 | Sale | 14.31 | 800 | 11,448 | 22,700 | Mar 14 05:32 PM | | ABRAMOWITZ KENNETH | Director | Mar 08 | Sale | 13.94 | 2,000 | 27,880 | 23,500 | Mar 12 04:58 PM | | ABRAMOWITZ KENNETH | Director | Mar 05 | Option Exercise | 2.61 | 800 | 2,088 | 27,500 | Mar 07 05:11 PM | | Sabat John R | S. VP, Sale, MKtg, Nat'l Accts | Dec 14 | Option Exercise | 1.71 | 139,830 | 238,773 | 100,638 | Dec 17 06:44 PM | | Sabat John R | S. VP, Sale, MKtg, Nat'l Accts | Dec 14 | Sale | 12.75 | 139,830 | 1,783,471 | 33,255 | Dec 17 06:44 PM | | Sabat John R | S. VP, Sale, MKtg, Nat'l Accts | Dec 13 | Option Exercise | 1.60 | 16,997 | 27,195 | 50,252 | Dec 17 06:44 PM | | Sabat John R | S. VP, Sale, MKtg, Nat'l Accts | Dec 13 | Sale | 13.10 | 16,997 | 222,661 | 33,255 | Dec 17 06:44 PM | | MEYER STEVEN J | Director | Dec 12 | Option Exercise | 1.50 | 30,000 | 44,900 | 75,799 | Dec 14 05:39 PM | | WEINSTEIN ALAN D | Director | Dec 12 | Buy | 13.59 | 11,200 | 152,208 | 20,200 | Dec 14 05:02 PM | | WEINSTEIN ALAN D | Director | Dec 12 | Buy | 13.71 | 19,300 | 264,603 | 69,300 | Dec 14 05:02 PM | | MEYER STEVEN J | Director | Dec 12 | Sale | 13.57 | 20,701 | 280,828 | 65,799 | Dec 14 05:39 PM | | WEINSTEIN ALAN D | Director | Dec 04 | Sale | 13.35 | 13,000 | 173,550 | 9,000 | Dec 06 05:57 PM | | WEINSTEIN ALAN D | Director | Dec 04 | Sale | 13.26 | 22,000 | 291,700 | 50,000 | Dec 06 05:57 PM | | ABRAMOWITZ KENNETH | Director | Nov 14 | Sale | 12.52 | 2,500 | 31,300 | 26,700 | Nov 16 05:25 PM | | Dick Timothy A | Chief Financial Officer | Oct 16 | Option Exercise | 1.00 | 45,100 | 45,100 | 77,921 | Oct 17 06:53 PM | | Dick Timothy A | Chief Financial Officer | Oct 16 | Sale | 13.00 | 45,100 | 586,305 | 32,821 | Oct 17 06:53 PM | | Dick Timothy A | Chief Financial Officer | Oct 15 | Option Exercise | 1.00 | 54,900 | 54,900 | 87,721 | Oct 17 06:53 PM | | Dick Timothy A | Chief Financial Officer | Oct 15 | Sale | 12.71 | 54,900 | 697,510 | 32,821 | Oct 17 06:53 PM | | Dick Timothy A | Chief Financial Officer | Sep 17 | Option Exercise | 1.00 | 100,000 | 100,000 | 132,821 | Sep 19 06:23 PM | | Dick Timothy A | Chief Financial Officer | Sep 17 | Sale | 14.08 | 100,000 | 1,407,990 | 32,821 | Sep 19 06:23 PM |
|
|
|
|
|
|
